Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 14/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.36 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2371278 | 0.86 | ERN1 (0.47) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL21884804 | 0.82 | ERN1 (0.44) | ERN1KDM4EPTGS2RAB9A | |
| SCHEMBL17841523 | 0.82 | ERN1 (0.44) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL22445291 | 0.82 | ERN1 (0.41) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL20607903 | 0.82 | ERN1 (0.45) | ERN1KDM4EPTGS2RAB9A | |
| SCHEMBL12865750 | 0.82 | ERN1 (0.44) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL29111409 | 0.81 | ERN1 (0.56) | ERN1KDM4EPTGS2RAB9APADI4 | |
| SCHEMBL31056823 | 0.79 | SELL (0.45) | ERN1KDM4EPTGS2 | |
| SCHEMBL23834937 | 0.78 | ERN1 (0.41) | ERN1 | |
| SCHEMBL31094206 | 0.78 | ERN1 (0.59) | ERN1TRIM24TRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2740734-B1 | HCV PROTEASE INHIBITORS | SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| EP-2740734-B1 | HCV PROTEASE INHIBITORS | SHANGHAI TANGRUN PHARMACEUTICALS CO LTD (CN) | 2017-09-06 | — | — | EP | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-8969373-B2 | HCV protease inhibitors | Shanghai Tangrun Pharmaceuticals Co., Ltd. (CN) | 2015-03-03 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| US-20140163219-A1 | HCV Protease Inhibitors | SHANGHAI TANGRUN PHARMACEUTICALS, CO., LTD. (CN) | 2014-06-12 | — | — | US | disclosed |
| EP-2740734-A1 | HCV PROTEASE INHIBITORS | Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) | 2014-06-11 | — | — | EP | disclosed |
| EP-2740734-A1 | HCV PROTEASE INHIBITORS | Shanghai Tangrun Pharmaceuticals, Co. Ltd (CN) | 2014-06-11 | — | — | EP | disclosed |
| WO-2013114040-A1 | NOVEL COMPOUNDS AND COMPOSITIONS USED AS ANTICANCER AGENTS | UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) | 2013-08-08 | — | — | WO | disclosed |
| WO-2013114040-A1 | NOVEL COMPOUNDS AND COMPOSITIONS USED AS ANTICANCER AGENTS | UNIVERSITE PARIS DIDEROT - PARIS 7 (FR) | 2013-08-08 | — | — | WO | disclosed |
| CN-102911254-A | HCV (hepatitis C virus) protease inhibitor | SHANGHAI TANGRUN MEDICAL TECHNOLOGY CO LTD | 2013-02-06 | — | — | CN | disclosed |
| WO-2007039609-A1 | PYRANODIBENZOFURAN DERIVATIVES WITH ANTIFUNGAL AND ANTIBACTERIAL ACTIVITY | INSTITUT PASTEUR (FR) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039609-A1 | PYRANODIBENZOFURAN DERIVATIVES WITH ANTIFUNGAL AND ANTIBACTERIAL ACTIVITY | INSTITUT PASTEUR (FR) | 2007-04-12 | — | — | WO | disclosed |
| US-6943191-B1 | Disubstituted lavendustin A analogs and pharmaceutical composition comprising the analogs | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-09-13 | — | — | US | disclosed |
| EP-1367046-A9 | Disubstituted lavendustin A analogs and pharmaceutical compositions comprising the analogs | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1367046-A1 | Disubstituted lavendustin A analogs and pharmaceutical compositions comprising the analogs | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1060160-A2 | DISUBSTITUTED LAVENDUSTIN A ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE ANALOGS | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999043636-A2 | DISUBSTITUTED LAVENDUSTIN A ANALOGS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE ANALOGS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THESECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163219-A1 | HCV Protease Inhibitors | CPN1, CTRL, CTSZ | ERN1 644/4885KDM4E 3281/4885PTGS2 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.